Valuation: GSK plc

Market Cap 80.29B 107B 93.73B 86.14B 152B 10,209B 155B 1,034B 402B 5,018B 402B 394B 17,292B P/E 2026 *
13x
P/E 2027 * 11.9x
Enterprise Value 95.27B 127B 111B 102B 181B 12,114B 183B 1,227B 477B 5,954B 478B 467B 20,519B EV / Sales 2026 *
2.81x
EV / Sales 2027 * 2.59x
Free-Float
92.29%
Yield 2026 *
3.47%
Yield 2027 * 3.64%
1 day+0.56%
1 week+1.75%
Current month+0.52%
1 month+8.95%
3 months-5.22%
6 months+11.08%
Current year+10.71%
1 week 22.44
Extreme 22.44
23.39
1 month 21.35
Extreme 21.35
23.39
Current year 20.27
Extreme 20.27
26.02
1 year 15.35
Extreme 15.35
26.02
3 years 14.68
Extreme 14.675
26.02
5 years 14.62
Extreme 14.62
27.13
10 years 14.62
Extreme 14.62
27.52
Manager TitleAgeSince
Chief Executive Officer - 2025-12-31
Director of Finance/CFO 64 2023-04-30
Chief Tech/Sci/R&D Officer - 2021-11-30
Director TitleAgeSince
Director/Board Member - 2026-05-05
Director/Board Member 64 2017-12-31
Chairman 68 2019-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%+1.75% - - 107B
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-0.08%+1.30%+32.15%+44.48% 292B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.94%+4.87%+31.78%+58.22% 411.08B
Weighted average by Cap. +2.19%+5.69%+42.24%+83.14%

Financials

2026 *2027 *
Net sales 33.86B 45.22B 39.53B 36.33B 64.22B 4,305B 65.2B 436B 170B 2,116B 170B 166B 7,293B 35.56B 47.48B 41.51B 38.15B 67.45B 4,521B 68.47B 458B 178B 2,222B 178B 174B 7,658B
Net income 6.47B 8.64B 7.55B 6.94B 12.27B 823B 12.46B 83.35B 32.4B 404B 32.44B 31.74B 1,394B 6.94B 9.26B 8.1B 7.44B 13.15B 882B 13.35B 89.32B 34.72B 433B 34.76B 34.02B 1,494B
Net Debt 14.98B 20.01B 17.49B 16.07B 28.42B 1,905B 28.85B 193B 75.01B 936B 75.09B 73.48B 3,227B 11.74B 15.67B 13.7B 12.59B 22.26B 1,492B 22.6B 151B 58.76B 734B 58.83B 57.57B 2,528B
Logo GSK plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
66,841
Date Price Change Volume
26-07-03 €23.39 +1.17% 1,175
26-07-02 €23.12 +1.81% 960
26-07-01 €22.71 -1.82% 957
26-06-30 €23.13 +0.78% 100
26-06-29 €22.95 +0.44% 802
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
20.15GBP
Average target price
20.95GBP
Spread / Average Target
+3.99%

Quarterly revenue - Rate of surprise